While we have relatively limited information regarding the prevalence of obsessive-compulsive disorder (OC) during pregnancy and the postpartum period. Previous studies have indicated that women may be more vulnerable to the onset of OCD during [...]
Postpartum depression (PPD) is a relatively common problem, affecting between 10% and 15% of women after delivery. Although it is difficult to reliably predict which women in the general population will experience postpartum depression, it [...]
This international survey demonstrates that pregnant and postpartum women are more likely to report elevated symptoms of depression, anxiety, and post-traumatic stress than others in the general population in the context of the COVID-19 pandemic.
Postpartum depression first gained medical attention in the 1970’s. While postpartum depression is similar to depression occurring at other times in a woman’s life, we have learned over time that many women with what we [...]
While the risk of severe COVID in pregnant women is relatively low, pregnant women with severe COVID experience worse outcomes. Some of our perinatal patients can’t wait to get a COVID-19 vaccine, some of our [...]
The COVID-19 pandemic has impacted the way antenatal care is being delivered in the United States, such as having fewer visits and replacing some in-clinic visits with virtual visits over telemedicine platforms. There has been [...]
In a given year, about 10% of mothers in the United States experience a major depressive episode (MDE). Roughly translated, this means about 1 in 10 children is exposed to maternal depression each year (Ertel [...]
Although new mothers describe breastfeeding as a meaningful and fulfilling aspect of caring for their infants, breastfeeding is also a common source of stress and anxiety. A recent study suggests that difficulties with breastfeeding may [...]
In 2019, brexanolone was introduced by Sage Therapeutics as Zulresso, a novel treatment for postpartum depression. The oral version of this novel antidepressant – SAGE 217 or zuranolone – is now finishing up its Phase [...]
While for some adults, attention-deficit/hyperactivity disorder (ADHD) is relatively mild and, with effective treatment, does not have a significant impact on overall functioning or quality of life. However, it is noteworthy that the majority of [...]
